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Abstract	  This	  paper	  quantifies	  the	  economic	  effect	  of	  the	  use	  of	  antiretroviral	  therapy	  as	  a	  frontline	  strategy	  to	  fight	  AIDS	  using	  data	  on	  29	  countries	  in	  Sub-­‐Saharan	  Africa.	  To	  this	  purpose,	  I	  use	   two-­‐stage	   least	   squares	  estimation	  defining	  both	  a	  health	  equation	  and	  an	  education	  and	  health	  capital-­‐augmented	  structural	  Solow	  growth	  equation.	  	  Through	  the	  introduction	  of	  antiretroviral	  therapy	  (ART)	  and	  HIV	  prevalence	  in	  the	  health	  equation,	  I	  indirectly	  link	  HIV	  and	  ART	  to	  economic	  growth.	  The	  results	  show	  that	   the	  HIV/AIDS	  epidemic	  reduces	  GDP	  per	  capita	  by	  0.175%	  per	  marginal	  increase	  in	  HIV	  prevalence.	  	  ART	  increases	  GDP	  per	  capita	   by	  0.048%	  per	  1%	   increase	   in	  ART	  provision.	  On	   average,	   this	   represents	   a	   0.5%	  higher	   GDP	   per	   capita	   per	   year	   attributable	   to	   ART	   in	   highly	   affected	   countries	   (HIV	  prevalence>20%).	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1)	  Introduction	  The	  development	  of	  anti-­‐retroviral	  therapy	  (ART)	  marked	  the	  transition	  of	  the	  AIDS	  epidemic	   from	   a	   deadly,	   highly	   morbid	   and	   costly	   disease,	   to	   a	   chronic	   condition	   with	  reduced	   health	   and	   economic	   implications.2	  The	   sexual	   transmission	   mechanism	   of	   the	  disease	   affects	   mainly	   the	   working	   population	   (15-­‐49	   year-­‐old	   adults),	   translating	   into	  negative	   economic	   outcomes.	   	   The	   reduction	   in	   productivity	   associated	   with	   AIDS	  morbidity	   and	   the	   shrinking	   of	   labor	   supply	   due	   to	   AIDS	  mortality	   could	   be	   potentially	  harmful	  for	  long	  run	  sustained	  growth	  (Dixon, McDonald, & Roberts, 2002).	  The	  increasing	  number	  of	  orphans,	  the	  negative	  effects	  on	  human	  capital	  accumulation	  and	  incentives	  to	  save	   and	   invest	   in	   education	   exacerbate	   the	   macroeconomic	   impact	   of	   AIDS.	   From	   	   the	  government's	  perspective,	  AIDS	  mortality	  leads	  to	  a	  reduction	  of	  the	  tax	  base	  (considering	  that	  it	  mostly	  affects	  working	  age	  population)	  translating	  in	  reduced	  revenue	  collection	  and	  an	   increase	   in	   the	   fiscal	   burden	   of	   the	   epidemic	   through	   treatment	   provision	   and	  healthcare	  costs.	  Also,	  by	  increasing	  mortality	  of	  the	  working	  population,	  AIDS	  undermines	  the	  base	  that	  sustains	  children	  and	  the	  elderly,	  putting	  pressure	  on	  the	  remaining	  working	  population	  to	  sustain	  a	  larger	  amount	  of	  dependents.	  	  	  The	  reduction	  of	  morbidity	  and	  mortality	  that	  ART	  has	  brought	  plays	  a	  crucial	  role	  in	  fighting	  the	  AIDS	  epidemic	  and	  its	  effects	  on	  growth	  and	  development.	  	  Recent	  scientific	  evidence	  suggests	  that	  the	  provision	  of	  antiretroviral	  therapy	  is	  of	  critical	  importance	  not	  only	  because	  it	  reduces	  AIDS	  related	  mortality	  and	  morbidity,	  but	  also	  as	  a	  way	  to	  reduce	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2	  The	  human	  Immune	  Deficiency	  Virus	  (HIV)	  is	  the	  pathogen	  that	  causes	  the	  Acquired	  Immune	  Deficiency	  Syndrome	  (AIDS).	  The	  morbidity	  effects	  of	  HIV	  are	  observable	  only	  when	  AIDS	  develops.	  Two	  parameters	  are	  used	  to	  diagnose	  AIDS:	  1)	  the	  CD4	  cell	  count	  drops	  below	  200/cc,	  or	  2)	  HIV	  related	  infections	  become	  symptomatic.	  The	  onset	  between	  initial	  infection	  and	  AIDS	  varies,	  averaging	  9-­‐11	  years.	  Death	  usually	  takes	  place	  1-­‐2	  years	  after	  the	  onset	  of	  AIDS	  related	  infections	  in	  the	  absence	  of	  ART	  (Santaeulalia-Llopis, 2008)	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incidence.	   At	   a	   global	   scale,	   there	   has	   been	   a	   19%	   decrease	   in	   AIDS-­‐related	   mortality	  between	  2004	  and	  2009,	  mainly	  due	   to	   the	   increase	   in	  provision	  of	  ART.	   	  ART	  has	  been	  associated	  with	   a	   92%	  decrease	   in	   risk	   of	   sexual	   transmission	  between	   sero-­‐discordant3	  partners.	   The	   provision	   of	   ART	   has	   been	   associated	   with	   a	   67%	   risk	   reduction	   of	  developing	  tuberculosis	  (TB)	  and	  a	  95%	  reduction	  in	  the	  risk	  of	  TB	  associated	  death.	  	  ART	  has	  reduced	  the	  number	  of	  HIV-­‐positive	  mothers’	  deaths	  and	   it	  has	  decreased	  the	  risk	  of	  mother-­‐to-­‐child	  transmission	  (UNAIDS,	  2010).	  All	  of	  this	  translates	  into	  a	  reduction	  in	  the	  burden	   placed	   on	   an	   already	   saturated	   healthcare	   system,	   a	   substantial	   reduction	   in	  healthcare	  expenses	  in	  the	  medium	  and	  long	  run	  and	  a	  decrease	  in	  the	  negative	  economic	  impacts	  of	  AIDS.	  The	   importance	   of	   antiretroviral	   therapy	   in	   fighting	   the	   HIV/AIDS	   epidemic	  motivates	  this	  paper.	  Unlike	  other	  papers,	  I	  attempt	  to	  quantify	  and	  understand	  the	  effect	  that	   ART	   has	   had	   in	   the	   already	   weakened	   economy	   of	   some	   highly	   affected	   African	  countries.	   I	   use	   an	   augmented	   Solow	   Growth	  model	   augmented	  with	   human	   and	   health	  capital	  to	  indirectly	  link	  HIV	  prevalence	  and	  ART	  provision	  to	  economic	  growth.	  I	  find	  that	  an	  increase	  of	  1%	  in	  HIV	  prevalence	  decreases	  GDP	  per	  capita	  by	  0.175%.	  The	  effect	  of	  a	  1%	  increase	  in	  ART	  provision	  is	  associated	  with	  an	  increment	  of	  0.048%	  in	  GDP	  per	  capita.	  	  This	  means	  that	  in	  a	  country	  with	  20%	  HIV	  prevalence,	  GDP	  per	  capita	  in	  a	  given	  year	  will	  be	   3.6%	   lower	   due	   to	   the	   economic	   burden	   of	   the	  HIV/AIDS	   epidemic.	   According	   to	   the	  estimates	   the	  high	  HIV	   countries	   in	   the	   sample	   on	   average	   a	   0.53%	   increase	   in	  GDP	  per	  capita	  per	  year	  due	  to	  ART	  provision	  since	  it	  massive	  distribution	  in	  2004.	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3	  Sero-­‐discordant	  means	  of	  different	  HIV	  status.	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2)	  Overview	  of	  the	  Epidemic	  	  It	  has	  been	  about	  30	  years	  since	  the	  first	  HIV	  case	  was	  identified.	  Over	  this	  period	  of	  time,	   65	   million	   people	   have	   been	   infected	   with	   the	   HIV	   virus	   and	   25	   million	   have	  succumbed	   to	   AIDS	   (a	   comprehensive	   review	   can	   be	   found	   in	   UNAIDS	  World	   AIDS	   Day	  report	   (2010)).4	  By	   the	   end	   of	   2010,	   34	   million	   people	   are	   living	   with	   HIV	   worldwide,	  which	  is	  equivalent	  to	  a	  17%	  increase	  from	  2001.	  This	  increase	  is	  both	  due	  to	  an	  increase	  in	   incidence	   and	  because	   of	   the	   increasing	   provision	   of	  ART,	  which	   significantly	   reduces	  mortality	  and	  morbidity	  and	  increases	  lifetime.	  	  	  	  Figure	  1.1	  shows	  how	  the	  HIV	  epidemic	  affects	  Sub-­‐Saharan	  Africa	  (SSA)	  more	  than	  any	  other	  region	  in	  the	  world.	  According	  to	  UNAIDS	  2011	  World	  AIDS	  Day	  Report,	  in	  2010	  68%	  of	  all	  people	  living	  with	  HIV	  were	  located	  in	  Sub-­‐Saharan	  Africa	  (which	  accounts	  for	  12%	  of	  the	  global	  population).	  Looking	  at	  the	  global	  2010	  incidence	  of	  HIV,	  SSA	  accounts	  for	  70%	  of	  the	  new	  infections	  in	  2010.	  This	  broad	  analysis	  is	  partially	  misleading	  because	  it	  does	   not	   indicate	   that	   although	   there	   is	   a	   large	   number	   of	   people	   living	  with	  HIV	   in	   the	  region,	  there	  has	  been	  a	  26%	  decrease	  in	  new	  infections	  from	  the	  peak	  of	  the	  epidemic	  in	  1997	  to	  2010	  in	  the	  region.	  	  The	   mid–term	   outcomes	   and	   major	   trends	   of	   the	   HIV	   epidemic	   have	   become	  discernible	  in	  some	  key	  demographic	  variables.	  For	  example,	  Figure	  1.2	  depicts	  the	  global	  	  number	  of	  AIDS-­‐related	  deaths	  for	  both	  adults	  and	  children	  between	  1990	  and	  2010.	  The	  graph	   shows	   how	   the	   epidemic	   has	   been	   growing	   relatively	   slowly,	   causing	   a	   higher	  number	  of	  deaths	  over	  time	  until	  2005,	  when	  HIV	  related	  deaths	  peak.	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  4	  This	  is	  half	  the	  number	  of	  deaths	  of	  the	  Second	  World	  War	  (1937-­‐1945)	  that	  amounted	  to	  55-­‐60	  million.	  The	  number	  also	  amounts	  to	  the	  30	  million	  deaths	  of	  the	  famine	  of	  the	  Chinese	  Great	  Leap	  Forward	  (1958-­‐1961).	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After	   this	   year,	   HIV-­‐related	   deaths	   steadily	   decreased.	   UNAIDS	   attributes	   the	   drastic	  change	  in	  the	  demographic	  variables	  of	  the	  most	  affected	  countries	  to	  the	  increase	  in	  ART	  provision	   (number	   of	   people	   receiving	   treatment)	   and	   services	   that	   increase	   its	  effectiveness	  (increasing	  and	  supporting	  proper	  adherence	  and	  counseling).5	  	  Reductions	   in	  price	  of	  ART	  enabled	   the	  massive	  deployment	  of	  ART	  as	  a	   frontline	  strategy	   to	   fight	   HIV/AIDS.	   These	   price	   reductions	   are	   the	   results	   of	   the	   introduction	   of	  generic	  ART	  and	  the	  mediation	  efforts	  of	  massive	  purchases	   led	  by	  organizations	   like	  the	  Global	  Fund	  and	  the	  Clinton	  Foundation	  (Vasan,	  Mukherjeem	  Farmer,	  Rosenfield,	  2006).	  	  	  	   	  
3)	  Literature	  Review	  Since	  the	  start	  of	  the	  HIV	  epidemic	  in	  1982,	  the	  highest	  demographic	  and	  economic	  impact	   has	   been	   felt	   in	   Sub-­‐Saharan	   Africa.	   According	   to	   the	   Joint	   United	   Nations	  Programme	  on	  HIV/AIDS	  (UNAIDS,	  2010),	  34%	  of	  the	  people	  living	  with	  HIV	  in	  the	  world	  are	  concentrated	  in	  10	  countries	  in	  southern	  Africa.	  	  A	  disproportionately	  large	  part	  of	  the	  global	  sero-­‐positive	  (HIV	  positive)	  population	  lives	  in	  this	  area	  and	  HIV-­‐related	  deaths	  are	  the	   highest	   there	   due	   to	   exacerbating	   factors	   such	   as	   poor	   nutrition,	   lack	   of	   access	   to	  healthcare	  and	  HIV	  testing,	  and	  poverty.	  The	  approaches	  to	  understanding	  and	  quantifying	  the	  relationship	  between	  HIV	  and	  growth	   are	   varied	   and	   propose	   different	   mechanisms.	   The	   most	   relevant	   research,	  McDonald	  &	  Roberts,	   2006,	   investigates	   the	   effect	   of	  AIDS	  on	   economic	   growth	  using	   an	  augmented	   Solow	   model.	   	   Their	   augmented	   Solow	   model	   consists	   of	   a	   Cobb-­‐Douglas	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  5	  Adherence	  means	  following	  the	  treatment	  regime	  both	  in	  timing	  and	  dose.	  Adherence	  not	  only	  maximizes	  the	  benefits	  of	  ART	  by	  preventing	  the	  virus	  to	  replicate	  but	  is	  also	  necessary	  to	  prevent	  mutations	  and	  drug	  resistance	  (US.	  National	  Institute	  of	  Health,	  2010)	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function	  with	  labor	  enhancing	  technology,	  labor,	  physical,	  human	  and	  health	  capital.6	  They	  use	  data	   for	   income,	   population,	   investment	   rates,	   and	   education	   from	   the	  World	  Bank’s	  Development	   Indicators	   and	   Global	   Development	   Finance	   database.	   	   The	   authors	   use	   a	  panel	  set	  of	  data	  for	  112	  countries	  over	  the	  period	  1969	  to	  1998.	  They	  find	  that	  an	  increase	  os	  1%	  in	  HIV	  prevalence	  decreases	  GDP	  per	  capita	  by	  0.59%.	  Ahuja,	  Wendell	   and	  Werner	   (2006)	  use	  male	   circumcision	   rates7	  as	  an	   instrument	  for	   HIV	   prevalence	   in	   order	   to	   investigate	   the	   relationship	   between	   AIDS	   and	   economic	  growth.	  The	  use	  of	  male	  circumcision	  as	  an	  instrument	  for	  HIV	  prevalence	  is	  appropriate	  because	   it	   is	   not	   correlated	  with	   any	  potential	   omitted	   variable	   at	   the	  national	   level	   like	  initial	   income,	   initial	   life	   expectancy	   or	  modernity.	   The	   basis	   for	   their	   approach	   derives	  from	   the	   measurement	   error	   that	   is	   likely	   to	   plague	   estimates	   of	   HIV	   prevalence,	   the	  problem	   of	   reverse	   causality	   between	   HIV	   prevalence	   and	  many	   economic	   indicators	   of	  growth,	  and	   the	  possibility	  of	  omitted	  variable	  bias.	  Male	  circumcision	  rates	  are	   likely	   to	  face	   none	   of	   the	   problems	   of	   endogeneity	   that	   arise	   when	   using	   other	   macro-­‐economic	  indicators.	  They	  measure	  economic	  growth	  and	  performance	  using	  crude	  death	  rate,	  infant	  mortality	   rate,	   GDP	   per	   capita,	   savings	   as	   percentage	   of	   GDP,	   crude	   birth	   rate,	   youth	  literacy	  rate	  and	  malnutrition	  rate.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  6	  The	  augmented	  Solow	  model	  follows	  a	  progression	  that	  starts	  with	  Mankiw,	  Romer	  and	  Weil	  who	  add	  human	  capital	  to	  the	  model	  (Mankiw,	  Romer	  &	  Weil,	  1992).	   Knowles and Owen subsequently add health capital 
(Knowles & Owen,1995). 	  7	  The	  relationship	  between	  male	  circumcision	  and	  the	  decrease	  in	  HIV	  has	  been	  explained	  mainly	  by	  two	  theories.	  The	  first	  one	  is	  that	  uncircumcised	  males,	  within	  a	  less	  sanitary	  environment,	  are	  more	  likely	  to	  become	  infected	  with	  chancroid	  infections	  that	  ulcer.	  The	  ulcers	  increase	  blood	  exposure,	  increasing	  the	  likelihood	  of	  HIV	  transmission	  (Caldwell	  &	  Caldwell,	  1996).	  The	  second	  theory	  proposes	  that	  there	  is	  a	  high	  concentration	  of	  Langerhans	  cells	  in	  the	  prepuce.	  Langerhans	  cells	  are	  known	  to	  be	  targets	  for	  HIV	  transmission,	  explaining	  why	  removing	  the	  prepuce	  would	  decrease	  the	  likelihood	  of	  transmission	  (Hussain	  &	  Lehner,	  1995).	  Prevalence	  of	  other	  sexually	  transmitted	  infections	  also	  increases	  the	  likelihood	  of	  HIV	  transmission	  by	  the	  same	  ulcer	  mechanism.	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Their	  first	  empirical	  strategy	  consists	  of	  two	  parts.	  	  First	  they	  divide	  a	  sample	  of	  49	  African	  countries	   into	  high	  1997	  prevalence	  (>	  6%)	  and	   low	  1997	  prevalence	  (<6%)	  and	  low	   (<20%),	   medium	   (20-­‐80%)	   and	   high	   (>80%)	   circumcision	   rates.	   They	   use	   HIV	  prevalence	  rate	  in	  1997	  as	  a	  proxy	  indicator	  for	  the	  average	  AIDS	  rate	  between	  1990	  and	  2005.	  	  They	  proceed	  to	  graphically	  analyze	  how	  each	  economic	  outcome	  is	  affected	  by	  the	  AIDS	   rate	   through	   time	   by	   level	   of	   circumcision	   and	   high/low	   AIDS	   rate.	   They	   find	   the	  economic	  effect	  of	  AIDS	  on	  African	  economies	  to	  be	  minimal:	   	  AIDS	  does	  not	  significantly	  affect	  GDP	  per	  capita,	  savings	  rate	  and	  fertility.	  Contrary	  to	  the	  results	  of	  my	  research	  they	  do	  find	  that	  AIDS	  is	  reducing	  the	  rate	  at	  which	  youth	  literacy	  is	  increasing	  (Ahuja,	  Wendell	  &	  Welker,	  2006).	  The	   most	   direct	   attempt	   to	   link	   HIV	   prevalence	   to	   economic	   growth	   is	   done	   by	  Bonnel	  (2000).	  His	  model	  is	  based	  on	  three	  equations:	  one	  that	  links	  economic	  growth	  to	  macroeconomic	  policy,	   institutions	  and	  other	  determinants	  of	  growth;	  a	  second	  that	  links	  institutional	  variables	  to	  HIV;	  and	  a	  third	  that	  attempts	  to	  explain	  the	  determinants	  of	  HIV	  prevalence.	   	   Bonnel	   finds	   that	   the	   effect	   of	   AIDS	   on	   economic	   growth	   is	   significant	   for	  African	  countries	  with	  high	  HIV	  prevalence.	  He	  estimates	  that	  for	  countries	  with	  high	  HIV	  prevalence	  (20%	  or	  more)	  there	  is	  a	  2.6%	  decrease	  in	  yearly	  economic	  growth	  and	  that	  for	  countries	  with	  low	  prevalence	  (less	  or	  equal	  to	  8%)	  there	  is	  an	  associated	  0.7%	  decrease	  in	  growth.	   The	   main	   concern	   with	   Bonnel’s	   work	   is	   that	   it	   a	   lacks	   theoretical	   framework.	  	  Additionally,	  here	  does	  not	  attempt	  to	  measure	  the	  effects	  of	  how	  ART	  might	  mitigate	  the	  effects	  of	  the	  AIDS	  epidemic.	  Bell,	  Devarajan	  and	  Gersbach	  (2006)	  take	  a	  different	  approach	  to	  gauge	  the	  effect	  of	  AIDS	  on	  economic	  outcomes.	  They	  predict	  that	  AIDS	  will	  provoke	  an	  economic	  catastrophe	  
	   10	  
in	  the	  long	  run,	  triggered	  by	  a	  vicious	  cycle	  of	  premature	  death	  of	  parents	  and	  stagnation	  of	  human	  capital	  accumulation	  of	  the	  offspring.	   	  AIDS	  plays	  a	  role	  in	  reducing	  the	  combined	  	  human	  capital	  endowment	  of	  the	  parents	  (if	  one	  of	  them	  dies)	  and	  leaving	  the	  child	  as	  an	  orphan	   (if	   both	   parents	   die).	   This	   affects	   the	   ability	   of	   the	   offsrping	   to	   transmit	   human	  capital	   (not	   only	   as	   education,	   but	   as	   care	   and	   nurture)	   to	   the	   coming	   generation.	   	   The	  increase	  in	  orphans	  and	  the	  vicious	  cycle	  described	  by	  their	  model	  implies	  that	  there	  will	  be	  growing	  income	  inequality	  across	  time.	  	  Overall,	   the	   research	   that	   has	   been	   done	   regarding	   AIDS	   and	   its	   effect	   on	   the	  economy	  has	   focused	  on	  measuring	  the	   impact	  of	   the	  disease	  through	  the	  many	  different	  channels	  outlined.	  There	  have	  been	  no	  econometric	  attempts	  to	  gauge	  the	  effect	  of	  ART	  on	  the	  dynamics	  between	  the	  AIDS	  epidemic	  and	  economic	  growth.	  This	  paper	  attempts	  to	  fill	  this	  gap	  in	  the	  literature.	  	  	  
4)	  Theory	  
4.1	  Augmented	  Solow	  Model	  In	  this	  section	  I	  develop	  the	  structural	  growth	  equation	  that	  I	  will	  use	  to	  gauge	  the	  effects	   of	   ART	   provision	   on	   economic	   growth.	   The	   model	   development	   follows	   the	  chronological	  order	  of	  the	  literature,	  starting	  with	  the	  traditional	  model	  proposed	  by	  Solow	  (Solow,	  1959),	  and	  the	  subsequent	  human	  capital	  augmented	  model	  developed	  by	  Mankiw,	  Romer	  and	  Weil	  (MRW,	  1992).	  MRW	  find	  that	  adding	  human	  capital	  to	  the	  model	  improves	  how	  it	   fits	  existing	  data.	  They	   focus	  mainly	  on	  human	  capital	  as	   investment	   in	  education,	  particularly	  elementary	  schooling.	  They	  omit	  high	  school,	  higher	  education	  and	  investment	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ψ	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (1)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
where:	  
Yit	  is	  output	  of	  country	  i	  at	  time	  t	  	  At	  is	  technology	  at	  time	  t	  (assumed	  to	  be	  homogeneous	  throughout	  countries)	  
Lit	  is	  labor	  of	  country	  i	  at	  time	  t	  
Kit	  is	  physical	  capital	  of	  country	  i	  at	  time	  t	  
Eit	  	  is	  education	  capital	  of	  country	  i	  at	  time	  t	  
Hit	  is	  health	  capital	  of	  country	  i	  at	  time	  t	  
α-­β-­ψ	  are	  physical,	  human	  and	  health	  capital	  elasticities	  with	  respect	  to	  output	  	  Dividing	  equation	  (1)	  by	  At	  Lit	  yields	  its	  intensive	  form:	  
€ 
yit = kitαeitβhitψ 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (2)	  where	   the	   variables	   in	   lower	   case	   represent	  quantities	  per	  unit	   of	   effective	  unit	   of	   labor	  (for	  example	  yit=Yit/At	  Lit).	  Assuming	   that	   labor	   grows	   at	   a	   country	   specific	   constant	   rate	   of	   ni	   ,	   technology	  grows	   at	   a	   time	   specific	   rate	   of	   gt,	   and	   that	   physical,	   education	   and	   human	   capital	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depreciate	  at	  a	  constant	  rate	  of	  δ,	  we	  can	  show	  (see	  Appendix	  1)	  that	  the	  augmented	  steady	  state	  output	  per	  capita8	  (y*it)	  is	  given	  by:	  	  
€ 
ln yit* = lnAi0 + gtt −
α + β+ψ
(1−α − β −ψ) ln(ni + gt +δ) +
α




(1−α − β −ψ) ln si
E +
ψ
(1−α − β −ψ) ln si
H
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (3)	  	  	  	  	  	  	  	  	  
	  where	  siH,	  siE,	  siH	  are	  the	  savings	  rate	  for	  physical,	  education	  and	  health	  capital	  respectively.	  	  Equation	  (3)	  is	  equivalent	  to	  MRW’s	  equation	  except	  for	  the	  added	  health	  capital	  term,	  its	  elasticity	  with	  respect	  to	  output	  ψ	  and	  the	  savings	  rate	  of	  health	  capital.	  	  Estimating	   equation	   (3)	   is	   complicated	   by	   the	   fact	   that	   disaggregated	   investment	  data	  is	  not	  readily	  available	  and	  probably	  non-­‐existent.	  Available	  investment	  data	  refers	  to	  physical	   capital,	  whereas	   human	   and	  health	   capital	   investments	   are	   likely	   to	   be	  missing.	  There	  is	  a	  way	  of	  overcoming	  this	  through	  the	  steady	  state	  condition	  in	  levels	  imbedded	  in	  equation	   (3).	   MRW	   used	   this	   condition	   to	   propose	   alternative	   formulations	   where	   the	  estimating	  equation	  is	  not	  in	  terms	  of	  rates	  of	  accumulation	  (refer	  to	  equation	  3)	  or	  levels,	  for	  example:	  
€ 
ln yit* = lnAi0 + gtt −
α











	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (4)	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  8	  Steady	  state	  means	  that	  the	  growth	  of	  the	  per	  capita	  stock	  of	  capital	  is	  0.	  This	  implies	  that	  investment	  is	  equal	  to	  depreciation	  and	  the	  change	  of	  per	  capita	  stock	  of	  capital	  remains	  unchanged	  given	  the	  current	  level	  of	  savings	  (Mankiw,	  2009).	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In	  Equation	  (4),	  h*it	  is	  a	  steady	  state	  quantity	  of	  health	  capital	  per	  effective	  unit	  of	  labor.	  Since	  Equation	   (3)	   is	  derived	  under	   the	  assumption	  of	  a	   steady	  state,	  equation	   (4)	  does	  require	  the	  assumption	  of	  a	  steady	  state.	  	  MRW’s	  method	  of	   formulating	  Equation	  (3)	   in	  terms	  of	   levels	  and	  not	  saving	  rates	  provides	  the	  empirical	  advantage	  of	  allowing	  to	  simultaneously	  use	  stock	  and	  savings	  data	  for	  the	  parts	  of	  the	  estimating	  equation.	  Using	  MRW’s	  method,	  I	  can	  linearize	  Equation	  (4)	  around	  the	  steady	  state	  level	  of	  income	  per	  effective	  unit	  of	  labor	  (y*it)	  	  
€ 
ln yit* − ln yi0* = (1− expλt )lnAi0 + gtt −
(1− expλt )α










* − (1− expλt )ln yi0*
	  	  	  	  	  	  	  (5)	  
	   Solving	  for	   ln	  y*i0	  	  and	  using	  standard	  panel	  notation	  yields	  the	  general	   form	  of	  the	  estimating	  equation	  that	  I	  will	  use:	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (6)	  
	  Where:	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  or	  	   	  




(1−α) 	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  or	  	   	  
€ 
xit1 = ln(ni + gt + d)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  and	  where 	  is	  the	  standard	  error	  term.	  	  	  There	  are	  some	  particularities	  of	  Equation	  (6)	  that	  make	  it	  different	  from	  a	  typical	  cross-­‐sectional	   estimating	   equation.	   First	   it	   allows	   for	   variation	   in	   the	   country’s	   rate	   of	  technology	  growth	  (gt),	  the	  initial	  level	  of	  technology	  (lnA0).	  	  Also,	  the	  estimating	  equation	  uses	   the	   time	  series	   information	  because	   it	   is	  being	  estimated	  as	  a	   two-­‐way	   fixed-­‐effects	  dynamic	  data	  panel.	  	  The	  technology	  variances	  between	  countries	  can	  be	  accounted	  by:	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (7)	  Equation	  (7)	  implies	  that	  all	  country	  differences	  depend	  in	  the	  random	  term	  ε.	  The	  term	  is	  a	  constant,	  invariant	  across	  countries.	  	  	  
4.2	  Health	  Equation	  The	   theoretical	   definition	   of	   health	   capital	   in	   a	   macroeconomic	   context	   that	   is	  suitable	  for	  this	  estimation	  is	  not	  clear-­‐cut.	  The	  exploration	  of	  the	  determinants	  of	  health	  mostly	  comes	  from	  the	  micro-­‐intensive	  derivation	  of	  the	  demand	  for	  health	  postulated	  by	  Grossman	   (1972).	   	   The	   determinants	   of	   the	   “shadow	   price”	   of	   health	   are	   not	   easily	  applicable	  to	  the	  macro	  estimating	  equation	  used	  in	  this	  paper.	  A	  more	  macro	  overview	  of	  the	   determinants	   of	   health	   is	   proposed	   by	   Genberg	   (1992),	   who	   concludes	   that	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macroeconomic	  changes	  and	  health	  outcomes	  are	  not	  evidently	  clear	  and	  that	  there	  is	  not	  enough	  evidence	  of	  causality	  between	  the	  two.	  	  Considering	  this,	  McDonald	  and	  Roberts	  (2005)	  propose	  that	  the	  second-­‐best	  option	  to	   theoretical	   formulations	   of	   health	   determinants	   is	   to	   propose	   a	   reduced	   form	   health	  equation.	   	  The	  components	  of	  the	  health	  equation	  they	  used	  are	  “guided	  by	  literature	  but	  do	   not	   represent	   structural	   relationships	   	   (McDonald	   &	   Roberts,	   2005).	   The	   reduced	  equation	  they	  propose	  is	  a	  function	  of	  a	  set	  of	  exogenous	  variables.	  These	  variables	  include	  lagged	   income	   given	   that	   there	   is	   evidence	   that	   higher	   income	   populations	   have	   higher	  health	  outcomes.	  Education	  capital	  and	  nutritional	  capital	  are	  also	  included	  given	  that	  they	  are	  both	  related	  to	  better	  health	  outcomes	  as	  well,	  particularly	  in	  developing	  countries.	  HIV	  prevalence	   and	   the	   proportion	   of	   the	   population	   at	   risk	   of	   malaria	   are	   included	   as	  exogenous	  health	  shocks.	  	  Through	  the	  health	  equation,	  I	  measure	  the	  impact	  of	  ART	  on	  reducing	  the	  effect	  of	  the	  HIV/AIDS	  epidemic	  on	  output	  per	  worker	  in	  the	  structural	  growth	  equation.	  	  I	  propose	  the	   introduction	   of	   more	   variables	   in	   the	   vector	   that	   McDonalds	   and	   Roberts	   (2006)	  developed.	  Antiretroviral	  provision	  is	  not	  only	  an	  effective	  way	  of	  reducing	  mortality	  and	  morbidity,	  but	  also	  reduces	  the	  probability	  of	  infection	  per	  unprotected	  sexual	  encounter.	  	  The	   last	   addition	   to	   the	   health	   capital	   equation	   is	   DTP	   immunization	   provision. Following	   the	   procedure	   of	  McDonald	   and	   Roberts	   (2006)	   to	   account	   for	   non-­‐linearities	  and	  possible	  lags,	  I	  also	  include	  lagged	  values	  of	  the	  variables,	  interactions	  of	  each	  variable	  with	  per	  capita	   income	  and	  the	  squared	  terms	  of	  each	  explanatory	  variable.	  The	  reduced	  form	  health	  equation	  is: 
€ 
xit4 =ϕxit−1 + ρP + ξt +ω i +wit  
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where	   ,	   	  P	   is	   ty	  ahe	  vector	  of	  exogenous	  variables	  explained	  above,	   	  stands	  for	  time	  effects,	   	  stands	   for	  country	  specific	  effects	  and	  
€ 
wit 	  is	   the	  error	   term.	  Time-­‐specific	  and	   country-­‐specific	   effects	   are	   necessary	   given	   that	   inherent	   time	   trends	   or	   country	  differences	  will	  distort	  the	  interpretation	  of	  my	  results	  and	  will	  need	  to	  be	  accounted	  for	  in	  the	  estimation.	  	   Using	  infant	  mortality	  rate	  as	  the	  dependent	  variable	  will	  capture	  the	  variance	  of	  the	  HIV	   shocks	   that	   affect	   mothers	   and	   is	   transmitted	   to	   the	   newborn.	   Given	   the	   variables	  included	   in	   the	   health	   equation,	   it	   will	   capture	   fluctuations	   in	   the	   general	   health	   of	   the	  population	   and	   it	   might	   even	   overestimate	   it,	   given	   that	   women	   are	   often	   a	   vulnerable	  group	   in	   low-­‐income	   settings.	   To	   pursue	   the	   direct	   impact	   of	   HIV	   on	   the	   working	  population,	  it	  would	  be	  ideal	  to	  have	  mortality	  by	  age	  cohorts,	  yet	  this	  would	  only	  capture	  the	  mortality	  and	  would	  not	  account	  for	  AIDS	  related	  morbidity.	  	  	  
5)	  Data	  
	  The	  main	  source	  of	  data	  for	  the	  structural	  growth	  equation	  is	  the	  World	  Bank	  World	  Development	   Indicators	   Database	   (World	   Bank,	   2010).9	  	   The	   panel	   includes	   29	   Sub-­‐Saharan	  countries	  from	  1983	  to	  2009	  (see	  Appendix	  2)	  Income	  data	  are	  real	  GDP	  per	  capita	  purchasing	  power	  parity	  adjusted.	  I	  calculate	  the	  investment	  rates	  from	  2005	  price	  data	  on	  GDP	  and	  domestic	  investment.	  	  	  For	   human	   capital	   as	   education,	   there	   are	   three	   series:	   primary,	   secondary	   and	  tertiary	  school	  enrollment	  rates	  available.	  I	  use	  primary	  school	  enrollment	  given	  that	  it	  has	  the	  most	  data	  for	  most	  countries.	  In	  many	  countries	  there	  is	  inconsistency	  in	  the	  collection	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  9	  Obtained	  from:	  http://databank.worldbank.org/ddp/home.do	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of	   data	   for	   secondary	   and	   tertiary.	   Primary	   school	   also	   could	   capture	   the	   effects	   of	  improvements	   in	   health	   in	   the	   poorest	   populations	   given	   that	   the	   likelihood	   of	   a	   person	  completing	  secondary	  schooling	  are	  less	  than	  of	  completing	  primary	  schooling	  The	  data	   for	   the	  health	  equation	  are	   limited	  by	  availability	  and	   length	  of	   the	   time	  series.	   Following	   McDonald	   and	   Robert’s	   (2005)	   approach,	   I	   use	   infant	   mortality	   rate.	  McDonald	   and	   Roberts	   (2006)	   argue	   that	   it	   would	   reflect	   the	   state	   of	   the	   health	   of	   the	  population	  by	  looking	  at	  the	  most	  vulnerable	  population.	  Infant	  mortality	  would	  be	  a	  better	  reflection	   of	   the	   quality	   aspect	   of	   health,	   but	   might	   overestimate	   shocks	   to	   the	   health	  capital	   that	   asymmetrically	   impact	   mothers.	   An	   ideal	   indicator	   would	   capture	   both	   the	  morbidity	  and	  mortality	  aspects	  related	  to	  the	  development	  of	  AIDS.	  	  HIV	   prevalence	   between	   15-­‐49	   years	   was	   obtained	   from	   the	   UNAIDS	   database	  AIDSinfo.10	  The	  series	  includes	  the	  time	  period	  between	  1990	  and	  2009.	  The	  method	  used	  to	  calculate	  these	  estimates	  is	  detailed	  in	  Schwartlander	  et	  al	  (1999).	  	  	  	  Total	   ART	   coverage	   is	   available	   from	   UNAIDS	   starting	   from	   2004.	   The	   use	   of	  antiretroviral	  therapy	  to	  fight	  HIV	  starts	  with	  the	  development	  of	  azidothymidine	  (AZT)	  in	  1987.	   Prior	   to	   then,	   since	   no	   effective	   therapy	   existed	   it	   is	   safe	   to	   assume	   that	   ART	  provision	  was	  zero.	  Additionally,	  the	  cost	  of	  ART	  when	  it	  was	  developed	  was	  around	  800	  dollars	  per	  month	  in	  the	  United	  States	  in	  1997.	  It	   is	  only	  with	  the	  introduction	  of	  generic	  nevirapine	  that	  the	  price	  of	  ART	  falls	   from	  750	  dollars	  per	  month	  in	  2000	  and	  30	  dollars	  per	  month	  in	  2003	  (Kumarasamy	  et	  al.,	  2005).11	  This	  means	  that	  after	  2000,	  ART	  became	  a	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  10	  Obtained	  from:	  http://www.aidsinfoonline.org	  	  11	  Nevirapine	  is	  a	  type	  of	  medicine	  called	  a	  non-­‐nucleoside	  reverse	  transcriptase	  inhibitor	  (NNRT).	  It	  works	  by	  disrupting	  one	  of	  the	  early	  steps	  in	  the	  HIV	  life	  cycle,	  called	  reverse	  transcriptation	  (National	  Institute	  of	  Health,	  2012)	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cost-­‐effective	   strategy	   in	   the	   fight	   against	   HIV	   and	   AIDS,	   when	   generic	   ART	   became	  available.	  	  The	  price	  of	  ART	   that	   is	  used	   to	   instrument	  ART	  provision	  comes	   from	  the	  World	  Health	   Organization’s	   Global	   Price	   Reporting	   Mechanism.12	  The	   price	   data	   is	   derived	   by	  adding	   up	   the	   price	   of	   lamivudine	   (3TC-­‐150	   mg.),	   nevirapine	   (NVP	   –	   200	   mg.)	   and	  staduvine	  (d4T-­‐300	  mg.),	  the	  most	  commonly	  used	  first	  line	  ART	  in	  low-­‐income	  countries.	  I	  obtain	  DPT	  (diphtheria,	  pertussis,	  tetanus)	  immunization,	  expressed	  as	  the	  percent	  of	  children	  between	  12-­‐23	  months	  old	  vaccinated,	  from	  the	  World	  Bank’s	  Health,	  Nutrition	  and	  Population	   Statistics	   database.13	  	   Protein	   intake	   supply	   in	   grams	  per	  person	  per	  day	  was	  obtained	  from	  FAO’s	  database	  FAOSTAT.14	  Table	   1	   below	   contains	   the	   summary	   statistics	   for	   the	   variables	   included	   in	   the	  regression	  analysis	  and	   from	  which	  calculations	  were	  made	  as	  well.	  ART	  provision	   is	   the	  one	  with	  the	  least	  available	  data	  given	  that	  its	  implementation	  has	  been	  relatively	  recent.	  HIV	  prevalence	  ranges	  from	  0.1	  to	  26.5%	  throughout	  1990-­‐2009.	  This	  stark	  difference	  puts	  in	  perspective	  the	  difference	  between	  high	  and	  low	  HIV	  prevalence	  countries.	  This	  is	  more	  evident	  when	  comparing	  Table	  2	  (High	  HIV)	  and	  Table	  3	  (Low	  HIV).	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  12	  Obtained	  from	  http://apps.who.int/hiv/amds/price/hdd/index.aspx	  	  13	  Obtained	  from	  http://databank.worldbank.org/ddp/home.do	  	  14	  Obtained	  from	  http://faostat.fao.org/default.aspx?lang=en	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Table 1. Summary Statistics for all countries 
Time period 1983-2009 





(% of 15-45 pop.) 
 




460 51006.36 110449.60 0 971556 
DPT Inmunization 
(% of childen 13-
23 months) 
 




580 6447475 7646427 156983 44300000 
GDP Per Capita 
(PPP adjusted 2005 
dollars) 
 





547 65.48293 22.08 17.47 99.73 
Daily Protein Intake 
(grams) 
 









534 86.34 28.40 13.20 166 
Investment 
(% of GDP) 
 




580 2.52 1.26 -7.53 9.77 	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Table 2. Summary Statistics for Mean Low HIV Prevalence countries (<6% in 1997) 
Time period 1983-2009 





(% of 15-45 pop.) 
 




6 11246.02 8328.40 1630.56 23549.00 
DPT Inmunization 
(% of childen 13-
23 months) 
 
27 54.86 13.61 26.91 73.44 









27 42.60 14.10 4.11 64.12 
Daily Protein Intake 
(grams) 
 









27 92.55 11.54 73.33 111.75 
Investment 
(% of GDP) 
 




27 2.54 0.37 1.70 3.03 	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Table 3. Summary Statistics for Mean High HIV Prevalence countries (>6% in 1997) 
Time period 1983-2009 





(% of 15-45 pop.) 
 




6 106794.50 71823.49 20060.50 212886.50 
DPT Inmunization 
(% of childen 13-
23 months) 
 
27 72.80 8.38 48.80 80.67 









27 42.22 12.62 23.00 64.00 
Daily Protein Intake 
(grams) 
 









27 76.01 6.51 59.58 85.18 
Investment 
(% of GDP) 
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6)	  Graphical	  Analysis	  This	  section	  focuses	  on	  a	  graphical	  analysis	  of	  the	  variables	  of	   interest	  throughout	  time.	   I	   follow	  Werker,	  Ahuja	   and	  Wendell	   (2006)	   and	  group	   countries	   in	   two	   categories:	  those	   with	   high	   HIV	   prevalence	   (1997	   HIV	   prevalence>6%)	   and	   those	   with	   low	   HIV	  prevalence	  (1997	  HIV	  prevalence<6%).	  I	  choose	  1997	  as	  the	  comparison	  year	  because	  this	  is	  often	  regarded	  as	  the	  year	  when	  the	  extensive	  spread	  of	  the	  epidemic	  took	  place.	  I	  then	  average	   the	   values	   for	   each	   year	   by	   the	   two	   groups	   described	   above	   for	   each	   of	   the	  variables	  of	  interest.	  	  The	  first	  variables	  of	  interest	  are	  mean	  GDP	  per	  capita	  and	  mean	  HIV	  prevalence,	  presented	  in	  Figure	  2.a	  and	  2.b.	  	  Figure	   2.a	   shows	   the	   time	   variation	   of	   GDP	   over	   time	   for	   both	   high	   and	   low	  HIV	  prevalence	  countries.	  The	  vertical	  times	  in	  the	  graphs	  represent	  two	  important	  years.	  The	  first	   line	   is	   1997,	   the	   year	   that	  was	   chosen	   to	   divide	   the	   countries	   in	   high	   and	   low	  HIV	  prevalence.	  The	  second	   line	   is	  2004,	   the	  year	  when	  UNAIDS	  starts	  recording	  data	  of	  ART	  provision.	  	  Both	   groups	   have	   a	   similar	   starting	   point.	   High	   HIV	   prevalence	   countries	   have	  higher	  GDP	  per	  capita	  during	  1983-­‐1994.	  This	   is	   reasonable	  given	   that	   the	  effects	  of	  HIV	  are	  not	  noticeable	  in	  the	  short	  run	  and	  the	  effects	  of	  the	  new	  infections	  during	  this	  period	  would	  be	  felt	  on	  average	  9-­‐10	  years	  after	  initial	  infection,	  when	  symptomatic	  AIDS	  related	  diseases	  appear.	  What	  is	  noticeable	  is	  that	  in	  the	  mid	  1990s,	  both	  high	  and	  low	  HIV	  groups	  experience	  a	  consistent	  increase	  of	  GDP	  per	  capita.	  The	  change	  is	  noticeably	  larger	  for	  low	  HIV	  countries,	  which	  manage	  to	  close	  the	  gap	  around	  2000	  and	  reach	  approximately	  5000	  dollars	  per	  capita	  in	  2009,	  doubling	  GDP	  per	  capita	  in	  around	  15	  years	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Figure	  2.a	  	  	  	  	  	  	  	   	  Figure	  2.b	  	  	  	  	  	  	  	  	  	  	  Figure	  2.c	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High	  HIV	   countries	   also	   experience	   growth,	   but	   it	   pales	   in	   comparison	   to	   the	   low	  HIV	  group.	  By	  2009,	  the	  gap	  between	  high	  and	  low	  HIV	  countries	  has	  reversed	  and	  stands	  at	  about	  1300	  dollars	  per	  capita,	  favoring	  low	  HIV	  countries	  Figure	   2.b	   shows	   the	   progression	   of	   the	   number	   of	   the	   mean	   sero-­‐positive	  individuals	   between	   15-­‐45	   years	   old	   separated	   by	   high	   HIV	   prevalence	   and	   low	   HIV	  prevalence.	  This	  graph	   indicates	  that	  countries	  with	  high	  HIV	  prevalence	   in	  1997	  did	  not	  only	   start	   with	   a	   higher	   HIV	   prevalence	   in	   1990,	   but	   had	   a	   remarkable	   rate	   of	   increase	  during	  the	  1990s,	  peaking	  at	  around	  2000	  and	  starting	  to	  decrease.	  The	  period	  of	  decrease	  of	   HIV	   prevalence	   seen	   starting	   during	   2000	   could	   potentially	   be	   attributed	   to	   ART	  provision	  and	  the	  implementation	  of	  prevention	  initiatives	  that	  reduce	  risky	  practices	  both	  sexual	  and	  in	  intravenous	  drug	  use.	  Figure	  2.c	  depicts	  the	  progression	  of	  ART	  over	  time.	  	  The	  graph	  indicates	  that	  countries	  with	  low	  HIV	  prevalence	  received	  overall	  substantially	  less	  ART	  than	  countries	  with	  high	  HIV	  prevalence.	  The	  two	  series	  start	  at	  different	  levels	  in	  2004,	  and	  diverge	  from	  there.	  The	  two	  series	  diverge	  so	  noticeably	  because	  there	  is	  a	  massive	  increase	  in	  ART	  provision	  in	  countries	  with	  high	  HIV	  prevalence,	  while	  the	  low	  HIV	  prevalence	  ART	  provision	  does	  not	  increase	  substantially	  during	  this	  5-­‐year	  period.	  It	  is	  logical	  to	  think	  that	  the	  countries	  that	  are	  most	  afflicted	  would	  receive	  the	  highest	  quantity	  of	  antiretroviral	  therapy,	  both	  to	  slow	  down	  the	  rate	  of	  transmission	  and	  alleviate	  the	  effects	  of	  morbidity	  of	  AIDS.	  As	  shown	  in	  the	  following	  graphs,	  there	  is	  suggestive	  evidence	  that	  ART	  provision	  has	  had	  a	  noticeable	  effect	  both	  in	  the	  micro	  and	  macro	  levels.	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Figure	  3.a	  shows	  the	  progression	  of	  life	  expectancy	  at	  birth	  over	  time.	  This	  graph	  is	  also	  suggestive	  because	   it	  shows	  that	   life	  expectancy	  for	   low	  HIV	  countries	  has	   increased	  and	  overall	  improved	  over	  time	  without	  any	  noticeable	  drops.	  On	  the	  other	  hand,	  high	  HIV	  countries	   have	   a	   higher	   life	   expectancy	   than	   low	  HIV	   prevalence	   countries	   in	   1983.	   Life	  expectancy	  peaks	  at	  around	  1990	  and	  decreases	  to	  1983	  low	  HIV	  levels.	  	  The	  drastic	  drop	  in	   life	  expectancy	  of	  high	  HIV	  countries	  supports	  the	  argument	  that	  HIV	  has	  substantially	  decreased	  the	  life	  prospects	  of	  the	  most	  afflicted	  nations	  	  Another	  important	  trend	  to	  notice	  is	  that	  the	  point	  at	  which	  life	  expectancy	  reaches	  its	  minimum	  seems	  to	  match	  with	  the	  period	  where	  ART	  began	  being	  intensively	  used	  to	  combat	  the	  contagion,	  morbidity	  and	  mortality	  of	  HIV/AIDS.	  	  According	  to	  UNAIDS,	  	  “at	  the	  end	   of	   2009,	   37%	   of	   the	   adults	   and	   children	   eligible	   for	   antiretroviral	   therapy	   were	  receiving	   it	   in	   the	   region	   overall,	   compared	  with	   only	   2%	   seven	   years	   earlier”	   (UNAIDS,	  2010).	  Figure	  3.b	  shows	  the	  progression	  of	  infant	  mortality	  rate	  over	  time.	  For	  both	  groups,	  there	  has	  been	  a	  steady	  decrease	  from	  the	  start	  of	  the	  series.	  There	  is	  a	  constant	  difference,	  with	  a	  lower	  infant	  mortality	  for	  high	  HIV	  prevalence	  countries.	  What	  is	  noticeable	  is	  that	  that	   in	   1991,	   the	   infant	   mortality	   rate	   for	   the	   high	   HIV	   prevalence	   countries	   starts	   to	  increase,	  closing	  the	  gap	  of	  infant	  mortality	  rate	  between	  the	  two	  groups.	  The	  time	  period	  is	   suggestive	   that	   this	   greater	   infant	   mortality	   observed	   in	   high	   HIV	   countries	   could	   be	  caused	  by	  increased	  perinatal	  transmission	  (mother	  to	  child).	  	  The	  second	  important	  time	  period	  is	  2000-­‐2009,	  where	  ART	  was	  introduced	  as	  part	  of	  the	  strategy	  to	  eliminate	  mother	  to	  child	  transmission.	  According	  to	  UNAIDS,	  in	  2009,	  an	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estimated	  370.000	  children	  were	  newly	  infected	  with	  HIV,	  representing	  a	  24%	  drop	  from	  the	  previous	  5	  years.	  	  Figure	  3.c	   indicates	   the	  progression	  of	   the	  population	  growth	  rate	  over	   time.	  Both	  high	   and	   low	  HIV	   countries	   experience	   a	   drop	   in	   population	   growth	   between	   1987	   and	  1992.	   	  After	   this	  point,	   low	  HIV	  countries’	  population	  growth	  rate	   increases	  and	  peaks	   in	  2000,	  experiencing	  a	  slight	  decline	  after	   this	  year.	  The	   trend	   for	  high	  HIV	  countries	  after	  the	   initial	  drop	   is	  a	  plateau	  (in	  contrast	   to	   the	   increase	  of	   low	  HIV	  countries)	  and	  then	   it	  drops	  to	  its	  minimum	  between	  2003	  and	  2004.	  After	  2004,	  high	  HIV	  countries	  experience	  a	  slight	  increase	  in	  population	  growth	  rates.	  	  From	   a	   theoretical	   perspective,	   it	   makes	   sense	   that	   AIDS	   would	   decrease	   the	  population	  growth	  rate.	   	  AIDS	  would	  do	   this	   in	   two	  ways:	  an	   increase	   in	  mortality	  and	  a	  decrease	  in	  fertility.	  Currently,	  AIDS	  related	  deaths	  account	  for	  20.4%	  of	  the	  total	  deaths	  in	  Sub-­‐Saharan	  Africa.	  This	  makes	  AIDS	  the	  leading	  cause	  of	  death	  in	  the	  region	  and	  the	  fourth	  cause	   of	   death	  worldwide	   (Jamison,	   Feachem,	  Makgoba,	   Bos,	   Baingana,	   Hofman	  &	   Rogo,	  2006).	  	  	  The	   decrease	   in	   fertility	   is	   supported	   by	   micro	   empirical	   evidence.	   Zaba	   and	  Gregson	   (1998)	   estimate	   that	   there	   is	   a	   0.4%	   decrease	   in	   fertility	   associated	   with	   1%	  increase	   in	  HIV	   prevalence,	  mainly	   due	   foetal	   loss	   associated	  with	  HIV	   infection	   and	   co-­‐infection	   of	   other	   sexually	   transmitted	   diseases.	   Fertility	   also	   is	   reduced	   by	   the	   risk	  perception	  of	  HIV	  contraction.	  As	  HIV	  prevalence	  increases,	  the	  demand	  for	  children	  falls	  in	  response	  to	  the	  perceived	  increase	  in	  the	  hazard	  of	  infection	  (Young,	  2005).	  Figure	  4.a	  shows	  the	  progression	  of	  protein	  intake	  throughout	  time.	  Protein	  intake	  is	  used	  in	  the	  included	  in	  the	  reduced	  health	  equation	  as	  a	  proxy	  for	  nutrition.	  In	  general,	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protein	  intake	  has	  increased	  over	  time	  for	  both	  groups.	  What	  is	  noticeable	  is	  that	  there	  is	  a	  10	  grams	  per	  day	  difference	  in	  1983	  between	  high	  and	  low	  HIV	  countries.	  The	  difference	  between	  protein	  intake	  converges	  as	  time	  passes	  and	  reaches	  a	  3	  grams	  per	  day	  difference	  in	  2009.	  	  	  Figure	  4.b	  shows	  the	  percent	  of	  children	  between	  12-­‐23	  months	  provided	  with	  DPT	  immunization.	  The	  steepest	  increase	  for	  both	  groups	  is	  observed	  in	  the	  1980s,	  noticing	  that	  high	  HIV	  prevalence	  countries	  have	  higher	  DPT	  immunization	  throughout	  the	  time	  period,	  and	   being	   the	   difference	   most	   stark	   in	   the	   1980s.	   It	   is	   relevant	   to	   include	   a	   proxy	   for	  vaccination	   given	   that	   it	  most	   certainly	   increases	   the	   health	   capital	   of	   the	   population	   by	  reducing	  the	  incidence	  of	  preventable	  diseases	  particularly	  in	  the	  infant	  population.	  Figure	   4.c	   shows	   the	   progression	   of	   gross	   capital	   formation	   over	   time.	   High	   HIV	  countries	  start	  at	  a	  substantially	  higher	  level	  of	  investment	  than	  low	  HIV	  countries.	  There	  is	  a	   lot	  of	  volatility	   in	   the	  series	   for	  both	  groups.	  Both	  countries	  converge	   in	   the	  end	  of	   the	  series,	  with	   low	  HIV	   countries	   having	   higher	   gross	   capital	   formation	   from	   2000	   on.	   The	  volatility	  could	  be	  an	   indicator	  of	  other	  conditions	   that	   factor	   in	   the	  perception	  of	  risk	  of	  investing	   in	   the	   country	   (corruption,	  political	   and	   social	  unrest,	   lack	  of	   solid	   institutions,	  etc.).	  Although	  the	  plot	  of	  both	  groups	  over	  time	   is	  hard	  to	   interpret,	   it	  could	  be	  possible	  that	  the	  decline	  in	  investment	  of	  high	  HIV	  countries	  can	  be	  partially	  explained	  by	  	  a	  shift	  in	  risk	  preference	  of	  investors	  given	  both	  the	  morbidity	  and	  mortality	  effects	  of	  AIDS	  on	  the	  working	  population.	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Something	  that	  must	  be	  noted	  is	  that	  all	  the	  previous	  graphs	  seem	  to	  indicate	  that	  prior	   to	   the	  development	  and	  widespread	  of	   the	  AIDS	  epidemic,	   countries	  with	  high	  HIV	  prevalence	  were	   in	   better	   conditions	   than	   low	  HIV	   prevalence	   countries.	   Countries	  with	  high	   HIV	   prevalence	   had	   a	   higher	   GDP	   per	   capita,	   higher	   life	   expectancy,	   higher,	   DPT	  immunization	   rates,	   higher	   protein	   intake	   per	   capita,	   investment	   and	   lower	   infant	  mortality	   rate	   during	   the	   start	   of	   the	   time	   series.	   The	   gap	   between	   the	   two	   groups	   got	  closer	  or	  even	  reversed	  particularly	  during	  the	  1990s,	  where	  the	  epidemic	  was	  spreading	  at	  a	  higher	  rate	  and	  the	  effects	  of	  the	  new	  infections	  in	  the	  previous	  decades	  would	  be	  felt.	  	  With	  the	  graphical	  analysis	  I	  have	  conducted,	  there	  are	  some	  interesting	  trends	  that	  match	  the	  peak	  of	  the	  epidemic	  and	  suggest	  that	  it	  has	  had	  an	  important	  effect	  both	  on	  the	  quality	  of	  living	  and	  in	  the	  rate	  of	  growth	  of	  countries	  with	  high	  HIV	  prevalence.	  Increases	  in	  ART	  seem	  to	  match	  increases	  in	  life	  expectancy,	  reductions	  in	  infant	  mortality	  rate	  and	  have	  managed	  to	  slow	  the	  rate	  of	  growth	  of	  the	  epidemic.	  	  Although	   the	  graphs	  provide	  a	  good	   intuition	  of	  what	  HIV	  has	  done	   to	  health	  and	  growth,	  I	  cannot	  obtain	  a	  valuation	  of	  how	  much	  it	  has	  affected	  growth	  through	  the	  effects	  of	  mortality,	  morbidity	  and	  demographic	  change.	  The	  same	  applies	  to	  ART	  provision.	  This	  leads	  us	  to	  test	  formally	  for	  the	  effect	  of	  ART	  on	  reducing	  the	  impact	  of	  AIDS	  on	  the	  growth	  of	  the	  nations	  of	  the	  sample.	  	  
	  
7)	  Econometric	  Method	  The	   model	   developed	   by	   McDonald	   and	   Roberts	   (2006)	   is	   composed	   of	   two	  equations:	  the	  growth	  equation	  derived	  from	  the	  augmented	  Solow	  model	  and	  the	  reduced-­‐	  form	   health	   equation.	   There	   are	   three	   econometric	   issues	   of	   concern.	   First,	   the	   health	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capital	  variable	  is	  endogenous	  in	  the	  growth	  equation,	  making	  it	  correlated	  with	  the	  error	  term,	  which	  biases	  the	  estimation	  not	  only	  of	  the	  endogenous	  regressor,	  but	  also	  of	  all	  the	  other	  covariates	  included	  in	  the	  regression.	  The	  second	  concern	  is	  that	  both	  the	  health	  and	  growth	  equations	  represent	  dynamic	  models	  containing	  lagged	  variables.	  This	  also	  leads	  to	  biased	   and	   inconsistent	   estimates	   if	   I	  were	   to	   use	   ordinary	   least	   square	   estimation.	   The	  third	  concern	  is	  that	  given	  the	  panel	  nature	  of	  our	  data,	   individual	  heterogeneity	  must	  be	  accounted	  for	  to	  produce	  reliable	  estimates.	  	  Instrumental	   variable	   estimation	   is	   used	   in	   two	   stages	   to	   deal	   with	   both	   the	  endogeneity	   of	   the	   health	   variable	   in	   the	   growth	   equation	   and	   the	   presence	   of	   lagged	  variables	  in	  both	  equations.	  	  The	  first	  stage	  obtains	  the	  health	  capital	  predicted	  values	  from	  the	   health	   equation.	   The	   lagged	   dependent	   variable	   is	   instrumented	   for	   using	   the	  exogenous	   variables	   in	   the	  model	   and	   further	   lags	   on	   the	   health	   term.	   The	   second	   step	  consists	   of	   using	   the	   predicted	   values	   obtained	   from	   the	   health	   equation	   in	   the	   growth	  equation.	  By	  doing	  this,	  I	  deal	  with	  the	  endogeneity	  of	  the	  health	  capital	  term	  on	  the	  growth	  equation.	  The	  growth	  equation	  is	  also	  estimated	  using	  instrumental	  variable	  estimation	  to	  deal	  with	  the	  lagged	  dependent	  variable.	  	  Hausman	  (1978)	  tests	  are	  used	  to	  investigate	  the	  need	  of	  including	  country	  specific	  effects.	  The	  Hausman	  test	  is	  used	  to	  determine	  if	  the	  fixed	  effects	  inclusion	  is	  appropriate.	  Since	  country	  specific	  effects	  are	  appropriate,	   I	  estimate	  the	  dynamic	  model	  using	  pooled	  data	   through	   the	   instrumental	   variable	   method.	   	   I	   use	   lagged	   levels	   of	   the	   dependent	  variable,	  predetermined	  variables	  and	  exogenous	  variables	  are	  used	  as	  instrument	  for	  the	  lagged	  dependent	  variable.	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   Considering	  that	  the	  growth	  equation	  has	  strong	  theoretical	  support,	   the	  variables	  are	  maintained	   in	   the	  equation	  even	   if	   they	  are	   statistically	   insignificant	  or	   they	  have	  an	  unexpected	   sign.	   This	   does	   not	   hold	   for	   the	   health	   equation,	  where	   a	   general	   to	   specific	  approach	  was	  used	  to	  determine	  what	  variables	  are	  relevant.	  The	  variables	  I	  include	  in	  the	  health	  equation	  are	  the	  lagged	  dependent	  variable,	  HIV	  prevalence,	  antiretroviral	  provision,	  current	  income,	  lagged	  income,	  protein	  intake	  and	  primary	  school	  enrollment.	  	  Additionally,	  I	   include	   interactions	  between	   income	  and	  all	   the	  explanatory	  variables	  and	   the	   squared	  explanatory	  variables.	  Both	  infant	  mortality	  rate	  and	  life	  expectancy	  are	  used	  as	  dependent	  variables	  in	  the	  health	  equation.	  	  
	  
7.1 Endogeneity	  Problems	  The	  inclusion	  of	  lagged	  variables	  in	  the	  health	  equation	  justifies	  the	  use	  of	  instrumental	  variable	  regression.	  To	  understand	  the	  full	  implications	  of	  endogeneity,	  I	  proceed	  to	  define	  and	  describe	  why	  endogeneity	  is	  a	  problem	  and	  what	  the	  instrumental	  variable	  regression	  does	  to	  solve	  it.	  	  	  Endogeneity	   occurs	   when	   the	   assumption	   that	   the	   errors	   are	   uncorrelated	   with	   the	  dependent	  variables	  is	  broken.	  This	  could	  happen	  because	  of	  measurement	  error,	  omitted	  variable	   bias	   or	   because	   of	   reverse	   causality	   between	   an	   explanatory	   variable	   and	   the	  independent	   variable.	   In	   this	   case	   the	   endogeneity	   problem	   arises	   with	   two	   variables:	  lagged	   infant	  mortality	  rate	  and	  ART	  coverage.	   I	  am	  trying	  to	  model	   the	  effect	  of	   the	  two	  last	  variables	  on	   infant	  mortality.	   It	  makes	  sense	   to	   think	   that	  countries	   that	  have	  higher	  infant	  mortality	  rate	  receive	  more	  of	  ART	  coverage	  to	  fight	  the	  higher	  incidence	  of	  perinatal	  transmission.	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When	   endogeneity	   is	   present,	   ordinary	   least	   squares	   can	   produce	   biased	   and	  inconsistent	   estimates.	   The	   presence	   of	   one	   endogenous	   variable	   distorts	   all	   of	   the	  coefficients	   of	   the	   model.	   	   In	   order	   to	   correct	   for	   endogeneity	   we	   need	   to	   look	   for	   an	  alternative	  covariate	  as	  a	  proxy	  for	  the	  endogenous	  covariate.	  A	  common	  approach	  is	  to	  lag	  the	  endogenous	  variable	  by	  one	  period	  or	  more.	  This	  is	  what	  McDonald	  and	  Roberts	  (2006)	  do	  when	  including	  the	  lagged	  infant	  mortality	  rate	  in	  the	  reduced	  health	  equation.	  This	  is	  simple	   to	   implement	   yet	   it	   comes	   at	   the	   cost	   of	   ease	   in	   interpretation	   of	   the	   lagged	  coefficient	   and	   decreased	   precision	   in	   some	   cases.	   Unfortunately,	   there	   is	   not	   empirical	  method	  of	  gauging	  the	  severity	  of	  the	  endogeneity	  or	  the	  efficacy	  of	  introducing	  the	  lagged	  variable.	   This	   brings	   us	   to	   the	   second	  method	   of	   dealing	  with	   endogeneity,	   instrumental	  variable	  regression.	  	  
7.2 Instrumental	  Variable	  Regression	  –	  Two	  Stage	  Least	  Squares	  An	  alternative	  for	  dealing	  with	  endogeneity	  is	  using	  instrumental	  variable	  regression.	  The	  method	  in	  essence	  consists	  of	  obtaining	  estimates	  of	  the	  potentially	  endogenous	  covariate	  using	   an	   instrumental	   variable.	   The	   essential	   part	   of	   this	   method	   is	   to	   find	   a	   genuinely	  exogenous	   instrumental	   variable	   that	   is	   correlated	  with	   the	   endogenous	   covariate	   but	   is	  only	  related	  to	  the	  dependent	  variable	  through	  the	  endogenous	  covariate.	  After	  obtaining	  the	  estimates,	  since	  they	  were	  derived	  from	  the	  exogenous	  instrumental	  variable,	  will	  not	  present	  the	  problem	  of	  endogeneity	  that	  the	  instrumented	  covariate	  had.	  This	   method	   is	   more	   rigorous	   and	   transparent	   than	   lagging	   the	   independent	  variable	  and	  it	  allows	  for	  empirical	  tests	  for	  the	  validity	  of	  the	  instruments	  being	  used.	  If	  a	  strong	   instrument	   is	   used,	   the	   estimates	   can	   be	   interpreted	   similarly	   to	   OLS	   and	   be	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consistent,	  unbiased	  and	  efficient.	  When	  using	  the	  TSLS	  (two	  stage	  least	  squares)	  models,	  three	   tests	  should	  be	  conducted	   to	  assess	   the	  severity	  of	   the	  bias	  due	   to	   the	  endogenous	  regressor,	  the	  relevance	  of	  the	  instrument	  used	  (whether	  it	   is	  sufficiently	  correlated	  with	  the	   endogenous	   regressor),	   and	   the	   exogeneity	   of	   the	   instrument	   (to	   what	   degree	   it	   is	  uncorrelated	  with	  the	  main	  equation	  residuals).	  Since	  the	  estimation	  depends	  completely	  on	  the	  strength	  of	  the	  instruments	  used,	  I	  can	  regress	  the	  potentially	  endogenous	  variable	  on	  the	  exogenous	  instruments	  and	  check	  for	   their	  magnitudes	  and	  significance.	  They	  should	  have	  sensible	   signs	  and	  be	  significant	  for	  the	  instrument	  to	  be	  valid.	  A	  high	  F-­‐statistic	  is	  desirable	  since	  it	  provides	  a	  test	  of	  joint	  significance.	  The	  second	  concern	  that	  needs	  to	  be	  addressed	  is	  the	  degree	  of	  endogeneity	  that	  the	  suspect	  endogenous	  covariate	  has.	  I	  can	  use	  the	  Hausman	  test,	  where	  the	  null	  hypothesis	  is	  that	  the	  regressor	  is	  exogenous	  to	  assess	  for	  endogeneity.	  	  	  If	  the	  test	  rejects	  the	  null	  at	  the	  10%	  level,	   there	  is	  need	  to	  be	  concerned	  about	  endogeneity	  of	  the	  suspect	  covariate.	  The	  intuition	  behind	  the	  Hausman	  test	   is	  equivalent	  to	  running	  the	  first	  regression	  where	  the	  endogenous	   covariates	   estimates	   are	   obtained	   and	   save	   the	   residuals.	   Then	   we	   should	  include	  the	  residuals	  as	  a	  covariate	  in	  the	  main	  equation	  and	  assess	  their	  significance.	  I	  am	  looking	   for	   the	   correlation	  between	   the	  dependent	  variable	   and	   the	   residuals	  of	   the	   first	  stage	  regression.	  	  
7.3 Fixed	  vs.	  Random	  effects	  –	  Accounting	  for	  country	  heterogeneity	  The	   third	   econometric	   concern	   mentioned	   previously	   is	   that	   country	   specific	  differences	  need	  to	  be	  accounted	  for	  in	  order	  to	  obtain	  reliable	  estimates	  in	  my	  regressions.	  From	   a	   theoretical	   point	   of	   view,	   I	   should	   expect	   that	   the	   inclusion	   of	   country	   specific	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effects	  in	  my	  model	  is	  sensible	  given	  the	  panel	  nature	  of	  the	  data	  and	  the	  heterogeneity	  in	  the	  countries	  that	  compose	  it.	  	  Fixed	  effects	  models	  should	  be	  used	  when	  each	  individual	  in	  the	  panel	   set	   of	   data	  has	   inherent	   characteristics	   that	  must	   be	   accounted	   for	   in	   order	   to	  obtain	   reliable	   estimates.	   In	   order	   to	   use	   a	   fixed	   effects	   model,	   I	   am	   assuming	   that	   the	  differences	  between	  countries	  are	   time	   invariant	  and	  uncorrelated	  between	  one	  another.	  	  These	   should	   be	   used	  when	   looking	   at	   different	   individuals	   over	   time.	   A	   random	   effects	  model	   assumes	   that	   the	   variation	   across	   entities	   is	   random	   and	   not	   correlated	  with	   the	  independent	   variables	   in	   the	   model.	   The	   random	   effects	   model	   assumes	   that	   the	  individual’s	   error	   term	   is	   not	   correlated	   with	   the	   predictors,	   allowing	   time	   invariant	  variables	  to	  play	  a	  role	  as	  explanatory	  variables.	  In	  order	  to	  formally	  test	  if	  I	  should	  use	  random	  or	  fixed	  effects	  models,	  I	  can	  conduct	  a	  Hausman	  test	  where	  the	  null	  hypothesis	  is	  that	  the	  random	  effects	  model	  is	  preferable	  over	  the	  fixed	  effects	  model.	   	  In	  order	  to	  conduct	  the	  test,	  I	  run	  a	  fixed	  effects	  model	  then	  save	  the	   estimates,	   and	   proceed	   to	   do	   the	   same	   with	   the	   random	   effects	   model.	   The	   saved	  estimates	  are	  used	  to	  run	  the	  Hausman	  test.	  	  
8)	  Estimation	  
	  
8.1 	  Health	  Equation	  
	  
	  
	  	  	  	  	  	  	  a)Testing	  for	  Instrument	  Relevance	  	  	   The	   introduction	   of	   the	   price	   of	   ART	   as	   the	   instrument	   to	   obtain	   theoretically	  endogeneity	  free	  estimates	  of	  the	  endogenous	  regressor	  ART	  provision	  calls	  for	  some	  tests.	  	  The	  tests	  aim	  to	  evaluate	  the	  strength,	  relevance	  and	  validity	  that	  will	  assure	  that	  the	  TSLS	  estimation	  presents	  unbiased	  coefficients.	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The	  first	  step	  is	  to	  test	  the	  relevance	  of	  the	  instruments	  being	  used.	  To	  do	  this,	  I	  run	  a	  regression	  of	  the	  endogenous	  regressor	  by	  all	  the	  exogenous	  regressors	  that	  will	  be	  used	  in	  the	  health	  equation.	  	  Table	  4	  presents	  the	  results	  of	  the	  regression.	  
Table 4. Regression Results for Instrument Relevance Testing 
Dependent Variable: ln(ART Provision) 
Variables                                             Estimate 
 























(0.12) *significant	  at	  10%	  	  	  	  	  	  **significant	  at	  5%	  	  	  	  	  	  ***significant	  at	  1%	  	  p-­‐values	  reported	  in	  parenthesis	  R-­‐Squared:	  0.56	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Observations:	  443	  	   The	   results	   of	   Table	   4	   show	   that	   the	   choice	   of	   ART	   price	   as	   an	   instrument	   is	  appropriate.	  The	  variable	  is	  significant	  and	  as	  expected	  has	  a	  negative	  sign.	  The	  magnitudes	  are	  sensible.	  The	  other	  exogenous	  variables	  are	  significant	  at	  the	  5	  and	  10%	  level.	  	  The	  F-­‐	  statistic	   of	   the	   model	   (12.33)	   indicates	   that	   the	   exogenous	   variables	   will	   serve	   as	   good	  instruments	  for	  the	  estimation.	  	  
b)	  Fixed	  vs.	  Random	  Effects	  –	  Time	  Specific	  Effects	  	  The	  nature	  of	  the	  data	  I	  am	  using	  suggests	  that	  I	  should	  include	  country	  fixed	  effects	  to	   account	   for	   country	  heterogeneity.	   I	   can	   formally	   test	   this	  by	   running	  a	  Hausman	   test	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between	  the	  fixed	  effects	  and	  the	  random	  effects	  model.	  The	  Hausman	  test’s	  p-­‐value	  is	  0.00,	  which	  ratifies	  the	  use	  of	  fixed	  effects	  as	  a	  sensible	  choice.	  	  The	  next	  step	  is	  to	  assess	  the	  need	  for	  the	  inclusion	  of	  time	  effects	  in	  the	  fixed	  effects	  model.	  For	  this	  I	  can	  include	  the	  time	  dummies	  in	  the	  fixed	  effect	  equation	  and	  perform	  a	  f-­‐test	  test.	  The	  null	  hypothesis	  if	  this	  test	  is	  that	  the	  time	  dummies	  are	  not	  jointly	  significant.	  That	  means	  that	  with	  a	  p-­‐value	  of	  less	  than	  0.10,	  I	  reject	  the	  null	  hypothesis	  and	  conclude	  that	   time	  effects	   should	  be	   included	   in	  my	  model.	  The	  p-­‐value	   for	   the	   test	   is	  0.07,	  which	  supports	  the	  inclusion	  of	  time	  specific	  effects.	  	  	  	  
c)	  Health	  Equation	  Estimation	  and	  prediction	  of	  Health	  Capital	  Given	   the	  specification	  of	  my	  model,	   the	  results	  of	   the	  health	  capital	  equation	  estimation	  are	  presented	   in	  Table	  5	  below.	  Only	   the	   coefficients	   that	  were	   statistically	   significant	  at	  the	  10%	  level	  are	  presented.	  	  The	  variables	  of	  interest	  have	  expected	  signs.	  ART	  provision	  therapy	  is	  negative	  and	  significant;	   the	   coefficient	   indicates	   that	   an	   increase	   of	   1%	   in	   the	   provision	   of	   ART	   is	  associated	  with	   a	   decrease	   of	   0.157%	   in	   infant	  mortality.	   As	   expected,	   increases	   in	   HIV	  prevalence	   are	   associated	   with	   increases	   in	   infant	   mortality.	   An	   increase	   of	   1%	   in	   HIV	  prevalence	   is	   associated	  with	  a	  0.21%	   increase	   in	   infant	  mortality.	  A	  percent	   increase	   in	  protein	   intake	   is	   associated	   with	   a	   0.20%	   decrease	   in	   infant	   mortality.	   	   Similarly,	   	   DPT	  immunization	  decreases	  infant	  mortality	  by	  0.3%.	  	  The	  coefficient	  for	  primary	  education	  is	  statistically	  significant	  at	  the	  10%	  and	  was	  considered	  when	  estimating	  health	  capital	   for	  the	  structural	  growth	  equation	  estimation.	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Table 5. Regression Results for Two Stage Least Squares Regression Health Capital    
…………. Estimation 
Dependent Variable: ln(Infant Mortality Rate) 









































Instrumented:	  ln(Infant	  Mortality t-1)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  ln(ART	  Provision)	   Instruments:	  All	  explanatory	  variables	  +	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  ln(ART	  Price)	  +	  ln(Infant	  Mortality t-3)	  	   	  	  *significant	  at	  10%	  	  	  	  	  	  **significant	  at	  5%	  	  	  	  	  	  ***significant	  at	  1%	  	  p-­‐values	  reported	  in	  parenthesis	  R-­‐Squared:	  0.89	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Observations:	  443	  The	   results	   in	   Table	   5	   can	   be	   compared	   to	   the	   results	   of	   a	   naïve	   regression	   that	   uses	  ordinary	   least	   squares	  and	  does	  not	  account	   for	   the	  endogeneity	  problem.	  The	   results	  of	  this	  regression	  are	  shown	  in	  Appendix	  3.	  The	  problem	  of	  endogeneity	  is	  obvious	  given	  the	  coefficients	  observed	  in	  Appendix	  3.	  The	  regression	  results	  of	  the	  naïve	  regression	  indicate	  that	  increases	  in	  GDP,	  DPT	  immunization,	  ART,	  education	  and	  protein	  intake	  are	  associated	  with	   an	   increase	   in	   infant	  mortality	   rate.	   The	   unexpected	   signs	   of	   the	   coefficients	   of	   the	  naïve	  regression,	  and	   the	  significance	  of	  some	   indicate	   that	   it	   is	  crucial	   to	  correct	   for	   the	  endogeneity	  that	  exists	  between	  ART	  provision	  and	  infant	  mortality	  rate.	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8.2 Structural	  Growth	  Equation	  	  After	  having	  estimated	   the	  predicted	  health	   capital	   from	   the	  health	   equation,	   the	   last	  component	  of	  the	  structural	  growth	  equation	  is	  available.	  The	  process	  of	  estimation	  of	  the	  structural	   growth	   equation	   is	   similar	   to	   the	   health	   equation	   because	   of	   the	   presence	   of	  lagged	   variables	   in	   the	   model	   and	   potential	   endogeneity	   concerns	   between	   the	   health	  capital	  term	  and	  income	  per	  capita.	  The	  results	  are	  presented	  in	  Table	  6	  below.	  The	  structural	  growth	  equation	  estimation	  indicates	  that	  the	  coefficient	  for	  investment	  is	   positive	   and	   significant	   as	   expected.	   The	   positive	   and	   significant	   sign	   of	   the	   lagged	  income	  per	  capita	   term	  indicates	   that	  convergence	   is	   taking	  place,	  with	  convergence	  rate	  given	   by	   the	   parameter	   λ.	   	   The	   coefficient	   for	   “capital	   widening/workforce	   growth”	  ln(n+g+d)	  is	  positive	  but	  not	  significant.	  Unexpectedly,	  the	  primary	  school	  coefficient	  is	  not	  significant	  at	   the	  5%	  level.	  The	  health	  capital	   is	  negative	  and	  significant	  at	   the	  10%	  level	  and	  its	  significance	  does	  not	  change	  when	  excluding	  the	  health	  capital	  from	  the	  equation.	  	  Once	  I	  have	  obtained	  the	  coefficients,	   it	   is	  possible	  to	  calculate	  the	  marginal	   impact	  of	  HIV	  on	  economic	  growth.	  From	  Table	  5,	  the	  coefficient	  for	  HIV	  prevalence	  is	  0.210,	  which	  means	  that	  a	  1%	  increase	  in	  HIV	  prevalence	  is	  associated	  with	  a	  0.21%	  increase	  in	  infant	  mortality.	  From	  Table	  6,	   the	  coefficient	   for	   the	  estimated	   infant	  mortality	   is	   -­‐0.820.	  Since	  the	  coefficient	   for	  HIV	  is	   the	  marginal	   increase	   in	   infant	  mortality	  rate,	   I	  can	  multiply	  the	  coefficient	   with	   the	   infant	   mortality	   estimate	   coefficient	   to	   obtain	   the	   reduction	   in	   GDP	  proportional	   to	  a	  1%	   increase	   in	  HIV	  prevalence.	   	   	  This	   is	   the	  number	   shown	   in	   the	  HIV	  impact	  row	  of	  Table	  6.	  	  The	  same	  principle	  can	  be	  applied	  to	  obtain	  the	  effect	  of	  a	  marginal	  increase	  in	  ART	  provision	  on	  GDP	  growth.	  The	  results	  show	  that	  an	  increase	  of	  1%	  in	  HIV	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prevalence	   decreases	   GDP	   per	   capita	   by	   0.18%.	   An	   increase	   of	   1%	   in	   ART	   provision	  increases	  GDP	  per	  capita	  growth	  by	  0.048%.	  	  
Table  6. Regression Results for Structural Growth Equation 
Dependent Variable: ln(GDP per capita) 



























λ                              0.015 
                            
HIV Impact                             - 0.175 
                             
ART Impact                               0.048 
                              *significant	  at	  10%	  	  	  	  	  	  **significant	  at	  5%	  	  	  	  	  	  ***significant	  at	  1%	  p	  values	  reported	  in	  parenthesis	  R-­‐Squared:	  0.98	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Observations:	  443	  Hausman	  Test	  p	  value:	  0.03	  –	  Fixed	  effects	  are	  appropriate	  	  	  	  	  	  	  	   The	   coefficient	   of	  HIV	  prevalence	   implies	   that	   a	   country	  with	  HIV	  prevalence	  of	   20%	  has	  a	  3.6%	  reduction	  in	  GDP	  per	  capita	  in	  a	  given	  year.	  Bonnel	  (2000)	  estimates	  the	  effect	  to	   be	   2.6%	   using	   the	   same	   20%	   prevalence	   benchmark.	   One	   potential	   reason	   for	   the	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difference	   in	   the	   estimates	   is	   that	   I	   use	   different	   theoretical	   approaches.	   Also,	   I	  incorporated	   more	   recent	   data	   of	   HIV	   prevalence	   that	   better	   reflects	   the	   effects	   of	   the	  epidemic	  over	  time	  given	  the	  relatively	  slow	  progression	  of	  HIV	  to	  AIDS.	  	  McDonald	  and	  Roberts	  (2006)	  estimate	  that	  a	  1%	  increase	  in	  HIV	  prevalence	  decreases	  GDP	  per	  capita	  by	  0.59%.	  It	  is	  possible	  that	  this	  is	  overestimating	  the	  effect	  of	  HIV	  on	  GDP	  per	  capita	  given	  the	  omission	  of	  a	  both	  ART	  and	  DPT	  immunization	  in	  the	  health	  equation.	  My	  estimate	  of	  the	  effect	  of	  AIDS	  in	  the	  economy	  varies	  from	  the	  other	  literature	  because	  of	  the	  different	  theoretical	  approach	  that	  I	  take.	  It	  would	  be	  ideal	  to	  have	  more	  data	  on	  male	  circumcision	  rates	  to	  be	  able	  to	  obtain	  more	  accurate	  estimates	  of	  HIV	  prevalence,	  yet	  this	  information	  is	  extremely	  limited	  and	  not	  readily	  available.	  	  	  
9)	  Discussion	  The	  results	  obtained	  from	  the	  health	  capital	  are	  consistent	  with	  what	  was	  expected.	  The	   decision	   to	   include	  DPT	   immunization	  provision	   and	  ART	  provision	   variables	   in	   the	  health	   equation	   seems	   to	   be	   sensible	   given	   the	   statistical	   significance	   and	   the	   expected	  signs	  of	  the	  variables.	  However,	  the	  magnitude	  of	  the	  ART	  coefficient	  could	  be	  misleading.	  	  	  The	   statistical	   significance	   and	   expected	  negative	   sign	   of	   the	   lagged	  GDP	   indicate	  that	   increases	   in	   income	   are	   related	   to	   improvements	   both	   in	   financial	   and	   social	  determinants	  of	  health.	  It	  is	  important	  to	  mention	  that	  the	  interpretation	  of	  the	  lagged	  GDP	  per	  capita	  could	  be	  misleading	  because	  it	  does	  not	  address	  important	  income	  distribution	  issues.	  Asymmetric	  distribution	  of	  income	  should	  be	  considered	  as	  a	  potential	  limitation	  of	  the	   interpretation	   of	   the	   results	   presented.	   	   The	   insignificant	   coefficient	   of	   primary	  education	   in	   the	  health	  equation	   is	   surprising.	  To	   check	   for	   this,	   the	  estimation	  was	  also	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done	   using	   secondary	   education.	   The	   coefficient	   using	   secondary	   education	   was	   also	  insignificant	   at	   the	   5%	   level.	   As	   expected	   the	   positive	   sign	   of	   the	   education	   coefficient	  indicates	  that	   increases	   in	  primary	  schooling	  decrease	   infant	  mortality.	  This	   is	  supported	  by	   the	   increased	   income	   derived	   from	   human	   capital	   accumulation	   and	   its	   subsequent	  impact	  on	  the	  health	  of	  the	  individual.	  Similarly,	   the	   coefficient	   for	   education	   human	   capital	   (ln(primary	   schooling))	   is	  insignificant	   at	   the	   5%	   level	   in	   the	   structural	   growth	   equation.	   The	   insignificance	   of	   the	  coefficient	   could	   be	   because	   of	   the	   choice	   of	   a	   Solow	   growth	   based	   economy.	   The	  developing	   economies	   are	   still	   constrained	  by	   agricultural	   production,	  which	  means	   that	  savings	  could	  not	  be	  an	  appropriate	  indicator	  of	  economic	  growth.	  Exploring	  this	  approach	  with	  a	  different	  model	  choice	  could	  produce	  interesting	  comparisons.	  	  
 
 10) Conclusion In	   order	   to	   quantify	   the	   impact	   of	   ART	   on	   economic	   growth,	   I	   defined	   a	   health	  capital	  equation	  that	  included	  lagged	  income,	  nutrition,	  education	  and	  DTP	  immunization	  to	   indirectly	   link	   HIV	   prevalence	   and	   ART	   to	   economic	   growth.	   Given	   the	   potential	  endogeneity	   problem	   between	   ART	   provision	   and	   infant	   mortality	   rate,	   I	   used	   price	   to	  instrument	   ART	   provision	   and	   included	   the	   endogeneity-­‐free	   estimates	   in	   the	   health	  equation	   estimation.	   The	   health	   equation	   infant	   mortality	   estimates	   are	   then	   used	   as	   a	  proxy	  for	  human	  capital	  in	  a	  second	  structural	  growth,	  Solow-­‐based	  growth	  equation.	  The	  structural	  growth	  equation	  includes	  physical,	  educational	  and	  health	  capital	  and	  it	  is	  used	  to	  estimate	  the	  effect	  how	  marginal	  increases	  in	  the	  different	  type	  of	  capitals	  affect	  growth.	  	  	  Through	   this	  mechanism,	   I	   calculate	  a	  marginal	   increase	   in	  HIV	  prevalence	  reduces	  GDP	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per	   capita	   by	   0.175%.	   Also,	   an	   increase	   of	   1%	   in	   ART	   provision	   is	   associated	   with	   a	  0.048%	  reduction	  in	  the	  effect	  that	  HIV	  has	  on	  GDP	  per	  capita.	  I	  argue	  that	  the	  magnitude	  of	   ART	   impact	   is	   not	   completely	   reflecting	   the	   positive	   effects	   it	   has	  when	   reducing	   the	  effect	  of	  the	  HIV/AIDS	  epidemic	  on	  economic	  growth.	  	  The	  long	  run	  advantages	  of	  providing	  ART	  will	  be	  substantially	  greater	  because	  ART	  not	   only	   reduces	   immunodeficiency	   related	   illness	   but	   also	   decreases	   the	   probability	   of	  transmission.	  This	  means	  that	  we	  will	  not	  only	  continue	  to	  see	  a	  decrease	  in	  the	  incidence	  over	  time	  given	  sustained	  that	  sustained	  ART	  provision	  is	  held,	  but	  also	  an	  increase	  in	  the	  number	  of	  people	  living	  with	  HIV	  as	  AIDS	  related	  deaths	  decline.	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Appendix	  1	  –	  Theoretical	  Derivation	  Starting	  with	  the	  intensive	  form	  of	  the	  Cobb-­‐Douglas	  production	  function	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (A1)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Where	  the	  variables	  written	   in	   lower	  case	  stand	  for	  quantities	  per	  effective	  unit	  of	   labor.	  We	   assume	   that	   the	   labor	   force	   grows	   at	   rate	   ni	   (country	   specific)	   and	   that	   technology	  grows	  at	  a	  rate	  gt	  (time	  specific).	  Both	  rates	  of	  growth	  are	  exogenously	  determined	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (A2)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (A3)	  The	  accumulation	  of	  physical,	  education	  and	  health	  capitals	  is	  determined	  by:	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (A4)	  
	  In	   the	   system	   of	   equations	   (A4)	   we	   assume	   that	   physical,	   education	   and	   health	   capital	  depreciate	  at	  the	  same	  rate	  δ.	  The	  equations	  above	  imply	  that	  the	  evolution	  of	  each	  type	  of	  capital	   is	  determined	  by	  the	   investment	   in	  each	  type	  of	  capital	  at	  period	  t-­‐1	  added	  to	  the	  already	  existing	  capital	  in	  the	  same	  period	  accounting	  depreciation.	  	  Savings	  are	  divided	  between	   investment	   in	  capital,	  education	  and	  health.	  These	  activities	  are	  treated	  as	  an	  investment	  activity	  such	  that:	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (A5)	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Since	   Equation	   (A5)	   implies	   that	   savings	   is	   a	   fraction	   of	   total	   income.	   The	   evolution	   of	  output	  per	  unit	  of	  effective	  worker	  is	  then	  determined	  by:	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (A6)	  
Assuming	  the	  existence	  of	  a	  steady	  state	  (α+β+ψ<1),	  system	  of	  equations	  (A6)	  would	  imply	  that:	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (A7)	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (A8)	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (A9)	  
Where	   the	   asterisk	   stands	   for	   the	   steady	   state	   values	   of	   the	   different	   types	   of	   capital.	  Sustituting	  (A7)	  to	  (A9)	  and	  (A3)	  in	  (A1)	  and	  taking	  the	  natural	  logarithms	  yields:	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (A10)	  
	  Equation	  (A10)	  is	  Equation	  (3)	  in	  the	  main	  text.	  	  	  	  	  
	   48	  
	  
Appendix	  2	  –	  Countries	  used	  in	  the	  analysis	  
Countries	  
High	  HIV	  Prevalence	  (>6%)	   Low	  HIV	  Prevalence	  (<6%)	  Botswana	  Central	  African	  Republic	  Kenya	  Cameroon	  Lesotho	  Malawi	  Namibia	  South	  Africa	  Swaziland	  Tanzania	  Uganda	  Zimbabwe	  	  	  	  	  	  	  
Angola	  Benin	  Burundi	  Burkina	  Faso	  Chad	  Comoros	  Dijibouti	  Equatorial	  Guinea	  Eritrea	  Gabon	  Madagascar	  Mali	  Mauritus	  Mozambique	  Rwanda	  Somalia	  Sudan	  Ethiopia	  12	   17	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Appendix	  3	  -­	  Ordinary	  Least	  Squares	  Analysis	  Given	  the	  model	  specification	  used	  by	  McDonald	  and	  Robertson	  (2006),	  the	  first	  naïve	  OLS	  regression	  below	  includes	  all	  the	  covariates,	  the	  lagged	  covariates,	  the	  squared	  covariates	  and	  the	  interactions	  of	  GDP	  with	  some	  of	  the	  covariates.	  The	  regression	  results	  using	  infant	  mortality	   rate	   are	   presented	   below.	   The	   table	   contains	   the	   regression	   using	   the	   main	  covariates	  without	  the	  lags,	  squared	  terms	  and	  interaction	  terms.	  
Regression Results for Naïve OLS 
 














































(-1.73)* *significant	  at	  10%	  	  	  	  	  	  **significant	  at	  5%	  	  	  	  	  	  ***significant	  at	  1%	  t-­‐statistics	  reported	  in	  parenthesis	  R-­‐Squared:	  0.99	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Observations:	  443	  
	   50	  
	  
